Results
|
|
1.
|
|
|
|
2.
|
|
|
|
3.
|
|
|
|
4.
|
|
|
|
5.
|
|
|
|
6.
|
|
|
|
7.
|
|
|
|
8.
|
|
|
|
9.
|
|
|
|
10.
|
|
|
|
11.
|
Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors. [electronic resource] by
- Salazar, Ramón
- Calles, Antonio
- Gil, Marta
- Durán, Ignacio
- García, Margarita
- Hidalgo, Manuel
- Coronado, Cinthya
- Alfaro, Vicente
- Siguero, Mariano
- Fernández-Teruel, Carlos
- Prados, Raquel
- Calvo, Emiliano
Producer: 20150302
In:
Investigational new drugs vol. 32
Availability: No items available.
|
|
|
12.
|
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin. [electronic resource] by
- Grosso, Federica
- D'Incalci, Maurizio
- Cartoafa, Mirela
- Nieto, Antonio
- Fernández-Teruel, Carlos
- Alfaro, Vicente
- Lardelli, Pilar
- Roy, Elena
- Gómez, Javier
- Kahatt, Carmen
- Soto-Matos, Arturo
- Judson, Ian
Producer: 20120803
In:
Cancer chemotherapy and pharmacology vol. 69
Availability: No items available.
|
|
|
13.
|
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors. [electronic resource] by
- Sessa, Cristiana
- Del Conte, Gianluca
- Christinat, Alexandre
- Cresta, Sara
- Perotti, Antonella
- Gallerani, Elisa
- Lardelli, Pilar
- Kahatt, Carmen
- Alfaro, Vicente
- Iglesias, Jorge L
- Fernández-Teruel, Carlos
- Gianni, Luca
Producer: 20140414
In:
Investigational new drugs vol. 31
Availability: No items available.
|
|
|
14.
|
Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease. [electronic resource] by
- Thariat, Juliette
- Etienne-Grimaldi, Marie-Christine
- Launay-Vacher, Vincent
- Soto-Matos, Arturo
- Fernandez-Teruel, Carlos
- Ghafari, Thomas
- Marcy, Pierre-Yves
- Milano, Gérard
- Renée, Nicole
- Gastaud, Lauris
- Thyss, Antoine
Producer: 20111227
In:
Cancer chemotherapy and pharmacology vol. 68
Availability: No items available.
|
|
|
15.
|
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule. [electronic resource] by
- Jimeno, Antonio
- Sharma, Manish R
- Szyldergemajn, Sergio
- Gore, Lia
- Geary, David
- Diamond, Jennifer R
- Fernandez Teruel, Carlos
- Soto Matos-Pita, Arturo
- Iglesias, Jorge Luis
- Cullell-Young, Martin
- Ratain, Mark J
Producer: 20180501
In:
Investigational new drugs vol. 35
Availability: No items available.
|
|
|
16.
|
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors. [electronic resource] by
- Massard, Christophe
- Margetts, Jane
- Amellal, Nadia
- Drew, Yvette
- Bahleda, Ratislav
- Stephens, Peter
- Stevens, Peter
- Armand, Jean Pierre
- Calvert, Hilary
- Soria, Jean Charles
- Coronado, Cinthya
- Kahatt, Carmen
- Alfaro, Vicente
- Siguero, Mariano
- Fernández-Teruel, Carlos
- Plummer, Ruth
Producer: 20131126
In:
Investigational new drugs vol. 31
Availability: No items available.
|
|
|
17.
|
Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen. [electronic resource] by
- Castellano, Daniel E
- Bellmunt, Joaquim
- Maroto, José Pablo
- Font-Pous, Albert
- Morales-Barrera, Rafael
- Ghanem, Ismael
- Suarez, Cristina
- Martín Lorente, Cristina
- Etxaniz, Olatz
- Capdevila, Laia
- Coronado, Cinthya
- Alfaro, Vicente
- Siguero, Mariano
- Fernández-Teruel, Carlos
- Carles, Joan
Producer: 20140715
In:
Cancer chemotherapy and pharmacology vol. 73
Availability: No items available.
|